Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

11p15 rearrangements (NUP98) in treatment related leukemia

Written2003-10Jean-Loup Huret
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9920/3 Therapy-related myeloid neoplasms
Atlas_Id 1299
Note This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into account per see), published in Genes,Chromosomes and Cancer in 2002.

Clinics and Pathology

Disease Treatment related myelodysplasia (t-MDS) or acute myeloid leukaemia (t-AML)
Note The study included 17 cases; t-MDS without progression to AML accounted for 35%, t-MDS with progression to AML for 18% and t-AML for the remaining 47% (M2 or M4 mainly); no case of acute lymphoblastic leukaemia
Epidemiology 11p15 rearrangements were found in 3% of t-MDS/t-AML and have been reported to be found in 5% of childhood t-MDS/t-AML; sex ratio: 4M/13F
Clinics Age at diagnosis of the primary disease 45 yrs (range 2-70); age at diagnosis of the t-MDS/t-AML: 50 yrs (range 4-75). Median interval was short: 54 mths (range: 11-189). Primary disease was a solid tumor in 47% of cases (in particular breast cancer) and a hematologic malignancy in 53%, treatment was chemotherapy (42%), or both chemotherapy and radiotherapy (58%). Treatment included topoisomerase II inhibitors in 71% of cases and alkylating agents in 76%.
Prognosis Median survival was 13 mths, with 56% of patients surviving at 1 yr, and 33% at 2 yrs., a similar survival to what is found in treatment related leukemias with a 21q22 rearrangement

Cytogenetics

Additional anomalies 11p15 rearrangements included inv(11)(p15q23) in 35% of cases, t(7;11)(p15;p15)in 18%, or, more rarely: t(1;11)(p32;p15), t(2;11)(q31;p15), t(4;11)(q22;p15), t(10;11)(q22-23;p15), t(11;17)(p15;q21), or t(11;20)(p15;q11); additional anomalies were: -7/del(7q) in 24%, and -5/del(5q) in 12 %. Complex karyotypes were found in 18%.

Result of the chromosomal anomaly

Hybrid gene
Description 5' NUP98 -3' partner
  

Bibliography

Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
Block AW, Carroll AJ, Hagemeijer A, Michaux L, van Lom K, Olney HJ, Baer MR
Genes, chromosomes & cancer. 2002 ; 33 (4) : 401-412.
PMID 11921274
 

Citation

This paper should be referenced as such :
Huret, JL
11p15 rearrangements in treatment related leukemia
Atlas Genet Cytogenet Oncol Haematol. 2004;8(1):16-16.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/11p15TreatRelLeukID1299.html


External links

arrayMapTopo ( C42) Morph ( 9920/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease database11p15 rearrangements (NUP98) in treatment related leukemia
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Jun 30 11:21:59 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.